The Israeli drug company thinks the biopharmaceutical drug developer will strengthen its position in its core central nervous system segment.
UnitedHealth will purchase outstanding Catamaran stock for $61.50 per share in cash. The deal is slated to close in the fourth quarter of this year.
Israeli drug company Teva Pharmaceutical Industries is buying Auspex Pharmaceuticals, with its portfolio of drugs to treat Tourette Syndrome, Huntington's chorea and a variety of other maladies.
U.S. stock futures are trending upward Monday as investors look to a short trading week with important economic data reports.
Teva said it would acquire smaller companies as a way to offset the expected revenue hit coming when its multiple sclerosis drug Copaxone faces generic competition in September.
Horizon is buying Hyperion to grow its orphan disease business unit.
The GFT505 study in NASH failed, analysts said. That's bad for Genfit and good for Intercept Pharmaceuticals, which is developing a rival drug for fatty liver known as OCA.
U.S. stock futures are sinking Friday at the end of a harsh week on the market. Investors will be looking to today's GDP and consumer sentiment numbers.
Weight Watchers International has come under fire for the sluggish pace of its turnaround effort, leaving investors hovering over its balance sheet waiting for evidence the tide is turning.
U.S. stock futures are falling even more after Wednesday's deep drop in stock prices.
If history repeats itself, the recent weakness in biotech stocks will end with lots more buying.
In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.
U.S. stock futures are mixed Wednesday on word of a major deal to combine Kraft Foods and H.J. Heinz.
These under-$10 biotech stocks are within range of triggering breakout trades.
Lukas Braunschweiler, CEO of Sonova, says the aging population is good for his company but the strengthening Swiss franc is not.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV